Stemade Biotech

stemade.com

Stemade Biotech Pvt. Ltd. Is the pioneer in the path-breaking concept of dental stem cells preservation in India, and is proud to be India’s first private dental stem cell bank. It provides an excellent opportunity for parents across India to safeguard their child’s health via flexible and affordable pricing plans. The collected dental stem cells can be potentially used to repair and cure 'tissue & organ related diseases' such as bone, cartilage, liver, diabetes, arthritis and many more. Stemade has pioneered this novel concept in India and Asia, having operations in more than 27 locations in India. Stemade aims to be present in at least 50 Indian cities within the first 2 quarters of this financial year. The company was established in year 2009 and launched commercial operations in November 2010. The company is spearheaded by Mr. Deepak Ghaisas, one of the pioneers of the IT revolution in India and has been Vice Chairman, Oracle Financial Services and CEO, iFlex India. Mr. Ghaisas is the first Indian CFO to win the prestigious CFO Asia Award.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

news image

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

news image

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More

Cell and Gene Therapy

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

news image

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More

Cell and Gene Therapy

GAMMA BIOSCIENCES AND LONZA COLLABORATE TO CO-DEVELOP REAGENTS FOR CLINICAL CELL SELECTION IN THE COCOON® PLATFORM

Gamma Biosciences | October 13, 2022

news image

Gamma Biosciences, a leading provider of tools and technologies for cell and gene therapy manufacturing, through their BioMagnetic Solutions business announced a strategic collaboration with Lonza. Under the multi-year agreement, BioMagnetic Solutions will supply its proprietary research and cGMP manufacturing grade FerroSelect™ reagents to Lonza for use in developing CAR-T and other immunotherapeutic products using Lonza's Cocoon® Platform. " Read More

news image

Cell and Gene Therapy

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More
news image

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More
news image

Cell and Gene Therapy

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More
news image

Cell and Gene Therapy

GAMMA BIOSCIENCES AND LONZA COLLABORATE TO CO-DEVELOP REAGENTS FOR CLINICAL CELL SELECTION IN THE COCOON® PLATFORM

Gamma Biosciences | October 13, 2022

Gamma Biosciences, a leading provider of tools and technologies for cell and gene therapy manufacturing, through their BioMagnetic Solutions business announced a strategic collaboration with Lonza. Under the multi-year agreement, BioMagnetic Solutions will supply its proprietary research and cGMP manufacturing grade FerroSelect™ reagents to Lonza for use in developing CAR-T and other immunotherapeutic products using Lonza's Cocoon® Platform. " Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us